Get the latest tech news

23andMe cuts 40% of staff in restructuring

23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The

The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials; it expects these changes to save $35 million annually. “We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO and co-founder Anne Wojcicki in a press release. In September, 23andMe’s entire board of directors — including Silicon Valley icons such as YouTube CEO Neal Mohan — resigned following Wojcicki’s attempt to take the company private in August.

Get the Android app